Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective

Wai Peng Lee | Spoorthi Sudhakar Shetty | Chin Mui Jaime Seah | Pei Ting Tan | Su Ming Tan

1Division of Breast Surgery, Department of Surgery, Changi General Hospital, Singapore, Singapore
2Clinical Trials and Research Unit, Changi General Hospital, Singapore, Singapore

Correspondence
Wai Peng Lee, Wai Peng Lee, Division of Breast Surgery, Department of Surgery, Changi General Hospital, Singapore 2 Simei Singapore.
Email: lee.wai.peng@singhealth.com.sg

Funding information
CGH Research Fund, Grant/Award Number: CHF2020.04-A

Abstract
Background: Ductal carcinoma in situ (DCIS) is an established precursor to invasive ductal carcinoma (IDC) and its coexistence with IDC appear to favor reduced biological aggressiveness. Its prognostic implication and ability to affect clinical outcome has been understudied in Asia. This study aims to explore if concomitant DCIS affects the clinical behavior and outcomes among Asians.

Aim: Stages I to III breast cancer patients with histological proven IDC, diagnosed and treated in a single institution from June 1, 2004 to June 30, 2014 were included in this study. Statistical analyses were conducted using $\chi^2$ test, independent t test, multivariate logistic regression and Kaplan–Meier test.

Methods and Results: A total of 818 patients were identified, including 224 and 594 patients with isolated IDC (No-DCIS) and IDC with coexisting DCIS (IDC-DCIS) respectively. Patients with IDC-DCIS were found to have smaller tumors (median: 22 mm, $p \leq 0.01$), estrogen receptor positivity ($p = 0.001$), progesterone receptor positivity ($p < 0.001$) and associated with better pathological stage ($p = 0.001$). Patients with No-DCIS were 1.6 times more likely to develop disease progression (95% CI: 1.1–2.3, $p = 0.027$) and subsequently associated with distant recurrences (20.5% vs. 13.6%, $p = 0.02$). The breast cancer specific 5 year overall survival rate for patients with No-DCIS and those with IDC-DCIS was 90.9% (95% CI: 86.2%–94.5%) and 93.7% (95% CI: 91.4%–95.5%), respectively ($p = 0.202$).

Conclusion: The presence of DCIS component in IDC among Asians is associated with favorable tumor biological profile, thereby indicating reduced disease aggressiveness. Our study is the first to report the clinical significance in terms of disease progression and distant recurrences among Asians.

KEYWORDS
breast cancer, breast tumor, disease, ductal carcinoma in situ, invasive breast cancer
1 | INTRODUCTION

Screening mammography has led to a rising detection of early breast cancer, namely ductal carcinoma in situ (DCIS). Though it has been assumed that invasive cancers are likely to have derived from pre-existing DCIS,\textsuperscript{1,2} IDC may still evolve de novo in up to 21.4% of cases worldwide. A delay in transformation from in situ to invasive form is believed to account for tumors with coexisting DCIS demonstrating lesser biological aggressiveness.\textsuperscript{3,4} Prior studies have linked tumors with IDC-DCIS with better clinical features such as smaller and lower grade tumors and lower probability of lymph node invasion. Nonetheless, it remains controversial if clinical outcomes such as recurrences and overall survival rates are affected.\textsuperscript{5,6} The clinical impact of concomitant DCIS in invasive cancers involving Asians has been understudied. Hence, our study aims to address if coexisting DCIS affects the tumor characteristics and clinical outcome such as recurrences, disease progression and overall survival among Asians.

2 | MATERIALS AND METHODS

A retrospective analysis was performed on our prospectively collected breast cancer database with an inclusion period from June 1, 2004 to June 30, 2014. This database comprises of patients who were diagnosed and underwent treatment in a specialized breast unit of a single hospital institution. Only patients with definitive histopathology diagnosis for invasive ductal carcinoma (IDC) were selected for evaluation. Patients diagnosed with metastatic disease were excluded. Patients with bilateral breast cancer were included as two separate study cases. Figure 1 showed the inclusion and exclusion criteria that resulted in our main study cohort of 818 patients.

Data collected include clinical characteristics, histopathological information and the type of surgery performed. The TNM classification was based on the latest edition of the American Joint Committee on Cancer at the time of reporting of the histopathology specimen.

Sentinel lymph node biopsy (SLNB) was performed in all patients with a preoperative diagnosis of infiltrative ductal carcinoma and in the absence of preoperative clinical or radiological evidence of nodal involvement. Axillary dissection was performed in patients who had preoperative diagnosis of axillary lymph node metastasis or macro metastasis on frozen section. Tumor histopathology and the number of lymph nodes involved were evaluated by routine hematoxylin-eosin (H&E) staining.

The cases were divided into two groups: invasive ductal carcinoma (No-DCIS) and invasive ductal carcinoma with ductal carcinoma in situ (IDC-DCIS).

This study had received the approval of the institutional ethics committee (IRB Ref No: 2019/2884).

Quantitative data are shown as median or mean of their values and their variability is expressed as range or SD, as specified for each analysis. Qualitative values are shown as absolute values or percentages. Categorical data were presented in frequency and percentage and association between subjects' characteristics and DCIS were tested using chi-square test.

Numerical data was presented in mean (standard deviation) and association was tested using independent t test if normal distribution was fulfilled. Otherwise, data were presented in median and interquartile rage (IQR) and Mann-Whitney U test was performed to test for the association between subjects' characteristics and DCIS status. Logistic regression was performed to identify the risk of developing disease progression between DCIS and non-DCIS patients.

\begin{figure}[h]
\centering
\includegraphics[width=\textwidth]{study_cohort_flow_diagram}
\caption{Study cohort flow diagram}
\end{figure}
| Variable                          | Total (n = 818) | No-DCIS (n = 224) | IDC-DCIS (n = 594) | p-value |
|----------------------------------|-----------------|-------------------|--------------------|---------|
| **Age mean years (SD)**          | 55.6 (13.5)     | 55.3 (14.5)       | 55.7 (13.1)        | .739    |
| **Age group**                    |                 |                   |                    |         |
| <40                              | 82 (10.0)       | 31 (14.5)         | 51 (8.6)           | .826    |
| 40–49                            | 224 (27.3)      | 50 (23.3)         | 174 (29.3)         |         |
| 50–59                            | 218 (26.7)      | 61 (28.5)         | 157 (26.4)         |         |
| 60–69                            | 147 (18.0)      | 41 (19.2)         | 106 (17.8)         |         |
| ≥70                              | 147 (18.0)      | 31 (14.5)         | 106 (17.8)         |         |
| **Ethnicity**                    |                 |                   |                    |         |
| Chinese                          | 588 (71.9)      | 162 (72.3)        | 426 (71.7)         | .397    |
| Malay                            | 135 (16.5)      | 42 (18.8)         | 93 (15.7)          |         |
| Indian                           | 46 (5.6)        | 9 (4.0)           | 37 (6.2)           |         |
| Others                           | 49 (6.0)        | 11 (4.9)          | 38 (6.4)           |         |
| **Follow-up duration**           | 93.7 (46.5)     | 91.6 (49.3)       | 93.8 (45.5)        | .541    |
| Invasive tumor size, median (mm) | 24 (15–35)      | 27 (18–45)        | 22 (14–31.3)       | .001    |
| **Tumor status n (%)**           |                 |                   |                    |         |
| 1                                | 358 (43.8)      | 78 (21.8)         | 280 (78.2)         | <.001   |
| 2                                | 379 (46.3)      | 106 (28.0)        | 273 (72.0)         |         |
| 3                                | 80 (9.8)        | 40 (50.0)         | 40 (50.0)          |         |
| **Nodal status n (%)**           |                 |                   |                    |         |
| 0                                | 501 (61.2)      | 130 (25.9)        | 371 (74.1)         | .752    |
| 1                                | 211 (25.8)      | 59 (28.0)         | 152 (72.0)         |         |
| 2                                | 93 (11.4)       | 28 (30.1)         | 65 (69.9)          |         |
| 3                                | 1 (0.1)         | 0 (0.0)           | 1 (100.0)          |         |
| **Overall Stage n (%)**          |                 |                   |                    | .001    |
| 1                                | 267 (32.6)      | 55 (20.6)         | 212 (79.4)         |         |
| 2                                | 435 (53.2)      | 125 (28.7)        | 310 (71.3)         |         |
| 3                                | 116 (14.2)      | 44 (37.9)         | 72 (62.1)          |         |
| **Tumor grade n (%)**            |                 |                   |                    | .171    |
| 1                                | 126 (15.4)      | 30 (23.8)         | 96 (76.2)          |         |
| 2                                | 272 (33.3)      | 62 (22.8)         | 210 (77.2)         |         |
| 3                                | 394 (48.2)      | 114 (28.9)        | 280 (71.1)         |         |
| **Presence of lymphovascular invasion n (%)** | | | | |
| Yes                              | 336 (43.4)      | 80 (39.6)         | 256 (44.7)         | .211    |
| No                               | 439 (56.6)      | 122 (60.4)        | 317 (55.3)         |         |
| **Estrogen receptor n (%)**      |                 |                   |                    | .001    |
| Positive                         | 579 (70.8)      | 135 (23.3)        | 444 (76.7)         |         |
| Negative                         | 230 (28.1)      | 81 (35.2)         | 149 (64.8)         |         |
| **Progesterone receptor n (%)**  |                 |                   |                    | <.001   |
| Positive                         | 494 (60.4)      | 110 (22.3)        | 384 (77.7)         |         |
| Negative                         | 315 (38.5)      | 106 (33.7)        | 209 (66.3)         |         |
| **Her2 receptor n (%)**          |                 |                   |                    | <.001   |
| Positive                         | 203 (24.8)      | 28 (13.8)         | 175 (86.2)         |         |
| Negative                         | 562 (68.7)      | 179 (31.9)        | 383 (68.1)         |         |
| **Menopausal status n (%)**      |                 |                   |                    | .940    |
| Pre-menopausal                   | 431 (53.9)      | 119 (54.1)        | 268 (46.2)         |         |
| Post-menopausal                  | 369 (46.1)      | 101 (45.9)        | 312 (53.8)         |         |
| **Surgical type n (%)**          |                 |                   |                    | .630    |
| Conservation                     | 170 (26.4)      | 49 (22.0)         | 121 (20.4)         |         |
| Mastectomy                       | 645 (73.6)      | 174 (78.0)        | 471 (79.6)         |         |

The bold and italic values will refer to significant p values (i.e., p < 0.05).
Survival analysis and duration to disease free progression between DCIS and non-DCIS were performed using Kaplan–Meier with log rank test to assess for statistical differences.

Propensity scores were calculated using a multiple Logistic Regression with clinical relevant variables: age, overall tumor stage, menopausal status, hormonal status, and cerB2 receptor status. Nearest-neighbor matching with maximum difference of 5% approach in 1:1 fashion was performed to match the propensity scores values of the DCIS and non-DCIS group.

Statistical significance was set at \( p < .05 \). Analysis was performed using SPSS version 21 (IBM Corp., Armonk).

### RESULTS

A total of 818 cases from June 1, 2004 to June 30, 2014 were included. No-DCIS was present in 224 (27.4%) cases while 594 (72.6%) had IDC-DCIS. The mean age at diagnosis was 55.6 years (42.1–69.1). The mean follow up period in our study was 93.7 months (47.2–140.2). The ethnic distribution of our study cohort was consistent with our national demographics. The clinicopathological features and the analysis between the two groups are shown in Table 1. Tumors were either T1 (43.8%) or T2 (46.3%). Tumors which were T3 made up 9.8% of the study population. Five hundred and one patients (61.2%) had no nodal involvement (N0). Patients were found to have Stage 1 (32.6%) and 2 (53.2%) cancer, followed by Stage 3 (14.2%). Patients with Stage 4 disease were excluded in the analysis due to their limited prognosis.

82.9% had presented with a clinically palpable breast lump. 13.1% were screen detected and hence, asymptomatic (Table S1). Others had nipple discharge, breast pain or skin changes and were subsequently found to have cancer on further evaluation. A higher proportion of asymptomatic women with IDC-DCIS were found to have suspicious mammographic findings on screening which had included microcalcifications as compared to the group with No-DCIS. This result was not found to be significant \( (p = .110) \) (Table S2). Nine patients presented with bilateral tumors, either synchronous or metachronous.

Lumpectomy was performed in 170 patients while 645 patients had mastectomy as a form of surgical treatment for their condition. One hundred and seventy four patients (78.0%) in the No-DCIS group and 471 (79.6%) in the IDC-DCIS group underwent mastectomy \( (p = .630) \).

Though majority of tumors in both groups were found to be grade 3 (48.2%), this result was not significant \( (p = .171) \). Similarly, there was no statistical significance upon comparison of the presence of lymphovascular invasion between both groups \( (p = .211) \).

The median size of the invasive tumor of the No-DCIS group was 27 mm while the IDC-DCIS group was 22 mm \( (p < .001) \). Patients with IDC-DCIS were associated with lower T stage \( (p < .001) \) and better overall pathological stage \( (p = .001) \). Furthermore, patients with IDC-DCIS were likely to express positivity in hormonal receptors (estrogen receptor, \( p = .001 \); progesterone receptor, \( p < .001 \)). One hundred and

### TABLE 2  Recurrences of the entire study population and No-DCIS and IDC-DCIS study groups

| Variable          | Total (\( n = 818 \)) | No-DCIS (\( n = 224 \)) | IDC-DCIS (\( n = 594 \)) | \( p \)-value |
|-------------------|------------------------|--------------------------|--------------------------|--------------|
| Local recurrence  |                        |                          |                          |              |
| Yes               | 48 (6.4)               | 17 (8.1)                 | 31 (5.8)                 | \( p = .746 \) |
| No                | 698 (93.6)             | 192 (91.9)               | 506 (94.2)               |              |
| Distant recurrence|                        |                          |                          |              |
| Yes               | 115 (15.5)             | 42 (20.5)                | 73 (13.6)                | \( p = .020 \) |
| No                | 627 (84.5)             | 163 (79.5)               | 464 (86.4)               |              |

The bold and italic values will refer to significant \( p \) values (ie. \( p < 0.05 \)).

### TABLE 3  Association between adjuvant therapy and risk of developing disease progression

| Variable          | Total (\( n = 818 \)) | No-DCIS (\( n = 224 \)) | IDC-DCIS (\( n = 594 \)) | \( p \)-value |
|-------------------|------------------------|--------------------------|--------------------------|--------------|
| Hormonal therapy  |                        |                          |                          |              |
| Yes               | 533 (65.2)             | 128 (57.1)               | 405 (68.2)               | \( p = .003 \) |
| No                | 270 (33.1)             | 92 (41.1)                | 179 (30.1)               |              |
| Chemotherapy      |                        |                          |                          |              |
| Yes               | 462 (56.5)             | 128 (57.1)               | 334 (56.2)               | \( p = .806 \) |
| No                | 338 (41.3)             | 91 (40.6)                | 247 (41.6)               |              |
| Radiation therapy |                        |                          |                          |              |
| Yes               | 323 (39.5)             | 100 (44.6)               | 223 (37.5)               | \( p = .051 \) |
| No                | 474 (57.9)             | 117 (52.2)               | 357 (60.1)               |              |

The bold and italic values will refer to significant \( p \) values (ie. \( p < 0.05 \)).

Survival analysis and duration to disease free progression between DCIS and non-DCIS were performed using Kaplan–Meier with log rank test to assess for statistical differences.

Propensity scores were calculated using a multiple Logistic Regression with clinical relevant variables: age, overall tumor stage, menopausal status, hormonal status, and cerB2 receptor status. Nearest-neighbor matching with maximum difference of 5% approach in 1:1 fashion was performed to match the propensity scores values of the DCIS and non-DCIS group.

Statistical significance was set at \( p < .05 \). Analysis was performed using SPSS version 21 (IBM Corp., Armonk).
seventy five patients (86.2%) with IDC-DCIS were found to demonstrate Her2 positivity while 28 patients with No-DCIS were found to be Her2 positive ($p < .001$). A total of 134 patients were found to have triple negative cancers. The mean duration of follow up was 93.7 months. Clinical outcomes have been summarized in Table 2. One hundred and fifteen distant recurrences were noted, with No-DCIS group having 42 (20.5%) and the IDC-DCIS group having 73 (13.6%) ($p = .020$). Forty eight local recurrences were recorded; No-DCIS group had 17 (8.1%) while IDC-DCIS group had 31 (5.8%) ($p = .72$).

Adjuvant therapy received by both groups has been summarized in Table 3. The odds ratio of developing disease recurrence in the group No-DCIS receiving hormonal therapy is 1.56 (95% CI: 1.05–2.32, $p = .027$). After adjusting for variables such as T and N stage, overall cancer stage, grade of tumor, presence of lymphovascular invasion, hormonal receptor status, this result was not significant (OR: 1.35, 95% CI 0.85–2.15, $p = .205$).

Patients with No-DCIS were 1.6 times more likely to develop disease progression in contrast to IDC-DCIS (OR: 1.6, 95% CI: 1.1–2.6, $p = .027$) but this risk was not significant after adjusting for T and N stage, overall stage, grade of tumor, presence of lymphovascular invasion, hormonal receptor status (OR:1.4 95% CI: 0.9–2.2, $p = .205$). Patients with IDC-DCIS had a longer mean of disease free progression as compared to those with No-DCIS (13.2 vs. 12.5 years) ($p = .014$).

The hazard ratio for disease free progression survival for the group with No-DCIS was 1.6 (95% CI 1.1–2.2) ($p = .014$).
Patients with IDC-DCIS recorded a longer mean survival than those with No-DCIS (14.0 vs. 13.5 years, \( p = .095 \)). Log rank test showed that this was not significant (\( p = .095 \)). Multivariate analysis showed that both IDC-DCIS and No-DCIS have similar hazard after adjusting for variables such as age at diagnosis, T and N stage, overall stage, presence of lymphovascular invasion, type of surgery and hormonal therapy. (HR: 1.3, 95% CI: 0.8–2.0, \( p = .307 \)) (Table 4). The 5 year disease free survival for patients with IDC-DCIS was 89.3% (95% CI 86.5%–91.9%) while the group with No-DCIS was 84.5% (95% CI 78.9%–89.2%) (\( p = .071 \)).

The breast cancer specific 5 year overall survival rate was performed in 163 pairs matched patients with the aid of propensity score matching (PSM) (Figure 2) and was 92.02% (95% CI 90.9%–94.7%). Cox proportion hazard ratio showed that patients with IDC-DCIS more likely to progress faster to death (Table 5). Adjustment by age, overall tumor stage, menopausal status, hormonal receptor, and cerB2 status showed no significant difference in the 5 year overall survival rate (\( p = .608 \)).

### TABLE 5 Utilization of Cox proportion hazard ratio

| Breast cancer related deaths (%) | Mean, years (95% CI) | HR (95% CI) | \( p \)-value |
|---------------------------------|----------------------|-------------|---------------|
| IDC-DCIS 25/163 (15.3)          | 13.30 (12.68, 13.92) | REF         |               |
| No-DCIS 21/163 (12.9)           | 13.56 (12.96, 14.17) | 0.86 (0.48, 1.54) | .608         |

Note: Adjustment for age, overall tumor stage, menopausal status, hormonal receptor, and cerB2 status. The bold and italic values will refer to significant \( p \) values (ie. \( p < 0.05 \)).

In Singapore, screening mammography is highly subsidized, making it extremely affordable for asymptomatic women. With the increasing awareness for screening mammography, detection of early mammary cancers including the in situ tumors have also been on the rise. However, current treatment guideline for breast cancer is dependent on the pathological characteristics of the invasive component. Systemic treatment does not depend on the in situ component (DCIS) of the tumor.

Invasive phenotype and this slow progression may suggest a possible favorable clinical prognosis.\(^7,8\) To date, only a handful of Western studies were able to recognize this association where the presence of concomitant in situ disease possibly led to better prognostic features and clinical outcomes.\(^9,10\) On the other hand, the role of DCIS in invasive mammary cancer and its clinical significance among the Asian population remains understudied.

Microcalcifications, first detailed by Salomon in 1913, have been said to be one of the earliest mammographic feature that may suggest underlying early breast cancer including DCIS.\(^12-14\) Nearly 90% of women with DCIS do not present with palpable tumor, therefore suspicious appearing microcalcifications could be the only suggestion in such asymptomatic women.\(^15,16\) Though our study results had suggested a higher proportion of asymptomatic women diagnosed with DCIS-IDC to have abnormal mammographic findings as compared to the group with No-DCIS, this finding was overall not significant. This could be because a large majority of our study subjects had

### DISCUSSION

Existing biological studies are able to demonstrate a difference between mammary cancers with No-DCIS and those with IDC-DCIS. The current understanding is that these mammary tumors undergo cellular differentiation from the in situ form of disease into the invasive phenotype and this slow progression may suggest a possible favorable clinical prognosis.\(^7,8\) To date, only a handful of Western studies were able to recognize this association where the presence of concomitant in situ disease possibly led to better prognostic features and clinical outcomes.\(^9,10\) On the other hand, the role of DCIS in invasive mammary cancer and its clinical significance among the Asian population remains understudied.
Our results indicated that IDC-DCIS is associated with smaller sized tumors and a lower overall clinical stage, thereby concuring with the hypothesis that tumors with concomitant DCIS were less biologically aggressive. Likewise, some studies have shown that tumors with concomitant DCIS are likely to express ER, PR, and cerB2 positivity as compared to tumors with No-DCIS. Logullo et al had analyzed 155 sequential cases of T1cN0M0 ductal cancers, of which 51 had the component of DCIS. No correlation between DCIS and estrogen, progesterone receptors were found. While M. Dieterich did show tumors with IDC-DCIS had better local recurrence survival rate as compared with those with pure IDC, there appeared to be no significant relationship between both groups of tumors and the hormonal markers that they expressed. Our study results showed that IDC-DCIS subjects were likely to express positivity in ER, PR, and cerB2 receptors and this was statistically significant. While our data suggest that IDC-DCIS cancers may imply a less aggressive phenotype for patients with hormonal receptor or Her2 receptor positive cancers, we do acknowledge that triple negative malignancies may exhibit different biological behavior. Furthermore, Her2 receptor positive tumors appear to be heterogeneous and in many instances, may demonstrate equal aggressiveness as compared to the triple negative cancers.

Researchers have since supported the preliminary theory of this slow evolution in deriving the invasive component and thereby resulting in a possibly better clinical prognosis. This study did demonstrate that the group with No-DCIS had higher percentage of distant recurrences compared to the group with IDC-DCIS (20.6% vs. 13.5%, p = .020). However, we were unable to draw a similar conclusion for local recurrence. This might be attributed to the small total number of patients in our cohort who had developed local recurrences over the surveillance period as a result of better compliance to local radiation therapy prescribed. Furthermore, a large proportion of our study subjects had undergone mastectomy, which might in turn lead to lower local recurrences. Our study results also suggest that patients with No-DCIS were 1.6 times more likely to develop disease progression as compared to those with IDC-DCIS, in spite of the adjuvant treatment given. These results add weight to the current speculation that the absence of coexisting DCIS is associated with poorer prognostic features and outcomes among Asian patients, especially in terms of distant recurrences and disease progression. Unfortunately, due to our small sample size of breast cancer related deaths, we were unable to detect a significant difference in the breast cancer specific 5 year overall survival between the two groups.

The breast cancer specific 5 year overall survival rate was analyzed with PSM. No significant results were found between the group with No-DCIS and IDC-DCIS (92.02%, 95% CI = 90.9%–94.7%, p = .608). PSM is regarded as an advanced statistical technique to minimize any possible confounders in an observational study. It serves to reduce possible treatment assignment bias and mimic randomization. We utilized PSM to assess if concomitant DCIS affects the 5 year breast cancer overall survival rate after adjusting for certain covariates as mentioned above but we were unable demonstrate a more favorable breast cancer specific 5 year overall survival rate. It might be attributed to the fact that both genomic profiles are highly similar.

Lastly, we do recognize the limitations of this study. Being a retrospective analysis, any incomplete data namely, less detailed histology reports in the early years of the 21st century, had to be excluded. Other information such as patients' details may have been missing during the early days of data entry. Other inherent biases associated with retrospective study have to be considered. Secondly, analysis of tumor specimens had been performed in the absence of central pathologic review, hence establishment of details such as presence of isolated tumor cells (ITC) infiltration and micro metastases (mic) in lymph nodes were absent. Thirdly, our sample size was too small to demonstrate a significant difference in the 5 year breast cancer specific survival. Unlike the Western studies, the clinical outcomes among Asians such as recurrences and disease free outcomes as a result from tumors with coexisting DCIS has been understudied. This study, with a long median follow up of 94 months, is to add weight to current findings and further strengthen the belief that coexisting DCIS does lead to better tumor profile. We are the first to document the clinical significance of concomitant DCIS in the presence of invasive cancers in terms of disease progression and distant recurrences.

5 CONCLUSION

With the limited data among Asian population, our study remains the first to demonstrate improved clinical outcomes in terms of disease progression and distant recurrences. Henceforth, this allows clinicians to better prognosticate and consider vigilant clinical surveillance of patients diagnosed with isolated IDC in remission.

AUTHOR CONTRIBUTIONS

Spoorthi Sudhakar Shetty: Data curation (supporting); investigation (supporting); project administration (lead). Chin Mui Jaime Seah: Data curation (lead); resources (supporting). Pei Ting Tan: Formal analysis (lead); methodology (supporting). Su Ming Tan: Methodology (supporting); writing – review and editing (lead). Wai Peng Lee: Conceptualization (lead); data curation (supporting); writing – original draft (lead).

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Wai Peng Lee https://orcid.org/0000-0001-6997-1524
REFERENCES

1. Burstein HJ, Polyak K, Wong JS, Lester SC, Kaelin CM. Ductal carcinoma in situ of the breast. N Engl J Med. 2004;350:1430-1441.

2. Sgroi DC. Preinvasive breast cancer. Annu Rev Pathol. 2010;5:193-221.

3. Dzierzanowski M, Melville KA, Barnes PJ, MacIntosh RF, Caines JS, Porter GA. Ductal carcinoma in situ in core biopsies containing invasive breast cancer: correlation with extensive intraductal component and lumpectomy margins. J Surg Oncol. 2005;90(2):71-76.

4. Logullo AF, Godoy AB, Mourão-Neto M, Simpson AJG, Nishimoto IN, Brentani MM. Presence of ductal carcinoma in situ confers an improved prognosis for patients with T1N0M0 invasive breast carcinoma. Braz J Med Biol Res. 2002;35(8):913-919.

5. Dieterich M, Hartwig F, Stubert J, et al. Accompanying DCIS in breast cancer patients with invasive ductal carcinoma is predictive of improved local recurrence-free survival. Breast. 2014;23:346-351.

6. Carabias-Meseguer P, Zapardiel I, Cusidó-Gimferrer M, et al. Influence of the in situ component in 389 infiltrating ductal breast carcinomas. Breast Cancer. 2013;20:213-217.

7. Wong H, Lau S, Yau T, et al. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer. 2010;102:1391-1396.

8. Chagpar AB, McMasters KM, Sahoo S, Edwards MJ. Does ductal carcinoma in situ accompanying invasive carcinoma affect prognosis? Surgery. 2009;146:561-567.

9. Sebastian Sebastian C, García Mur C, Cruz Ciria S, et al. Imaging and histologic prognostic factors in triple-negative breast cancer and carcinoma in situ as a prognostic factor. Radiología. 2016;58:283-293.

10. Goh CW, Wu J, Ding S, et al. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes. J Cancer Res Clin Oncol. 2019;145:1877-1886.

11. Gradishar WJ, Anderson BO, Balassanian R, et al. Invasive breast cancer version 1.2016. NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:324-354.

12. Castronovo V, Bellahcene A. Evidence that breast cancer associated microcalcifications are mineralized malignant cells. Int J Oncol. 1998;12(2):305-308.

13. Del Turco MR, Mantellini P, Ciatto S, et al. Full-field digital versus screenfilm mammography: comparative accuracy in concurrent screening cohorts. AJR Am J Roentgenol. 2007;189(4):860-866.

14. Morgan MP, Cooke MM, McCarthy GM. Microcalcifications associated with breast cancer: an epiphenomenon or biologically significant feature of selected tumors? J Mammary Gland Biol Neoplasia. 2005;10(2):181-187.

15. Rauch GM, Hobbs BP, Kuerer HM, et al. Microcalcifications in 1657 patients with pure ductal carcinoma in situ of the breast: correlation with clinical, histopathologic, biologic features, and local recurrence. Ann Surg Oncol. 2016;23(2):482-489.

16. Hofvind S, Iversen BF, Eriksen L, Styr BM, Kjellevold K, Kurz KD. Mammographic morphology and distribution of calcifications in ductal carcinoma in situ diagnosed in organized screening. Acta Radiol. 2011;52(5):481-487.

17. Kim JY, Han W, Moon HG, et al. Grade of ductal carcinoma in situ accompanying infiltrating ductal carcinoma as an independent prognostic factor. Clin Breast Cancer. 2013;13(5):385-391.

18. Wong H, Lau S, Yau T, Cheung P, Epstein RJ. Presence of an in situ component is associated with reduced biological aggressiveness of size-matched invasive breast cancer. Br J Cancer. 2010;102(9):1391-1396.

19. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Stürmer T. Variable selection for propensity score models. Ann Transl Med. 2019;7(18):484.

SUPPORTING INFORMATION

Additional supporting information may be found in the online version of the article at the publisher’s website.

How to cite this article: Lee WP, Shetty SS, Seah CMJ, Tan PT, Tan SM. Does concomitant ductal carcinoma in situ affect the clinical outcome in breast cancer patients with invasive ductal carcinoma: An Asian perspective. Cancer Reports. 2022;5(9):e1646. doi:10.1002/cnr2.1646